Literature DB >> 15835895

Solution structural study of a DNA duplex containing the guanine-N7 adduct formed by a cytotoxic platinum-acridine hybrid agent.

Hemanta Baruah1, Marcus W Wright, Ulrich Bierbach.   

Abstract

[PtCl(en)(ACRAMTU-S)](NO(3))(2) (PT-ACRAMTU; en = ethane-1,2-diamine, ACRAMTU = 1-[2-(acridin-9-ylamino)ethyl]-1,3-dimethylthiourea) is a dual metalating/intercalating DNA binding drug conjugate that shows cytotoxicity at micromolar to nanomolar concentrations in a wide range of solid tumor cell lines. In approximately 80% of its adducts, PT-ACRAMTU binds to guanine-N7 in the major groove, selectively at 5'-CG sites [Budiman, M. E. et al. (2004) Biochemistry 43, 8560-8567]. Here, we report the synthesis, physical characterization, and NMR solution structure of a site-specifically modified octamer containing this adduct, 5'-CCTCGTCC-3'/3'-GGAGCAGG-5', where the asterisk indicates the [Pt(en)ACRAMTU)](3+) fragment. The structure was determined by a combination of high-resolution 2-D NMR spectroscopy and restrained molecular dynamics/molecular mechanics (rMD/MM) calculations using 179 NOE distance restraints and refined to an r(6) weighted residual (R(x)) of 9.2 x 10(-)(2) using the complete relaxation matrix approach. An average structure was calculated from the final ensemble of 19 rMD geometries showing pairwise root-mean-square deviations of <1.05 A. The dual binding increases the thermal stability of the octamer compared to the unmodified duplex (DeltaT(m) = 13.2 degrees ). The modified sequence shows structural features reminiscent of both B- and A-type DNA. Watson-Crick hydrogen bonding is intact at and beyond the adduct site. Platinum is bound to the N7 position of G5 in the major groove, and ACRAMTU intercalates into the central 5'-C4G5/C12G13 base-pair step on the 5'-face of the platinated nucleobase. The chromophore's long axis is aligned with the long axes of the adjacent base pairs, maximizing intermolecular pi-pi stacking interactions. PT-ACRAMTU lengthens (rise, 6.62 A) and unwinds (twist, 15.4 degrees ) the duplex at the central base-pair step but does not cause helical bending. No C3'-endo deoxyribose pucker and no significant roll are observed at the site of intercalation/platination, which clearly distinguishes the PT-ACRAMTU-induced damage from the 1,2-intrastrand cross-link formed by cisplatin. Overall, the DNA perturbations produced by PT-ACRAMTU do not appear to mimic those caused by the major cisplatin lesion. Instead, intriguing structural similarities are observed for PT-ACRAMTU's monoadduct and the N7 adducts of dual major-groove alkylating/intercalating antitumor agents, such as the pluramycins.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15835895     DOI: 10.1021/bi050021b

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  20 in total

1.  Replacement of a thiourea with an amidine group in a monofunctional platinum-acridine antitumor agent. Effect on DNA interactions, DNA adduct recognition and repair.

Authors:  Hana Kostrhunova; Jaroslav Malina; Amanda J Pickard; Jana Stepankova; Marie Vojtiskova; Jana Kasparkova; Tereza Muchova; Matthew L Rohlfing; Ulrich Bierbach; Viktor Brabec
Journal:  Mol Pharm       Date:  2011-08-17       Impact factor: 4.939

2.  Using a build-and-click approach for producing structural and functional diversity in DNA-targeted hybrid anticancer agents.

Authors:  Song Ding; Xin Qiao; Gregory L Kucera; Ulrich Bierbach
Journal:  J Med Chem       Date:  2012-10-25       Impact factor: 7.446

3.  Comparative chemogenomics to examine the mechanism of action of dna-targeted platinum-acridine anticancer agents.

Authors:  Kahlin Cheung-Ong; Kyung Tae Song; Zhidong Ma; Daniel Shabtai; Anna Y Lee; David Gallo; Lawrence E Heisler; Grant W Brown; Ulrich Bierbach; Guri Giaever; Corey Nislow
Journal:  ACS Chem Biol       Date:  2012-09-05       Impact factor: 5.100

4.  New minor groove covering DNA binding mode of dinuclear Pt(II) complexes with various pyridine-linked bridging ligands and dual anticancer-antiangiogenic activities.

Authors:  Andjela A Franich; Marija D Živković; Tatjana Ilić-Tomić; Ivana S Đorđević; Jasmina Nikodinović-Runić; Aleksandar Pavić; Goran V Janjić; Snežana Rajković
Journal:  J Biol Inorg Chem       Date:  2020-03-11       Impact factor: 3.358

5.  Unusual Reactivity of a Potent Platinum-Acridine Hybrid Antitumor Agent.

Authors:  Leigh A Graham; Gary M Wilson; Tiffany K West; Cynthia S Day; Gregory L Kucera; Ulrich Bierbach
Journal:  ACS Med Chem Lett       Date:  2011-09-08       Impact factor: 4.345

6.  Design of a platinum-acridine-endoxifen conjugate targeted at hormone-dependent breast cancer.

Authors:  Song Ding; Xin Qiao; Gregory L Kucera; Ulrich Bierbach
Journal:  Chem Commun (Camb)       Date:  2013-03-25       Impact factor: 6.222

Review 7.  The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs.

Authors:  Timothy C Johnstone; Kogularamanan Suntharalingam; Stephen J Lippard
Journal:  Chem Rev       Date:  2016-02-11       Impact factor: 60.622

8.  Using fluorescent post-labeling to probe the subcellular localization of DNA-targeted platinum anticancer agents.

Authors:  Song Ding; Xin Qiao; Jimmy Suryadi; Glen S Marrs; Gregory L Kucera; Ulrich Bierbach
Journal:  Angew Chem Int Ed Engl       Date:  2013-02-20       Impact factor: 15.336

9.  Discovery of a Chiral DNA-Targeted Platinum-Acridine Agent with Potent Enantioselective Anticancer Activity.

Authors:  Shenjie Zhang; Xiyuan Yao; Noah H Watkins; P Keegan Rose; Sofia R Caruso; Cynthia S Day; Ulrich Bierbach
Journal:  Angew Chem Int Ed Engl       Date:  2020-09-29       Impact factor: 15.336

10.  Synthesis and biological evaluation of platinum-acridine hybrid agents modified with bipyridine non-leaving groups.

Authors:  Alexander R Kheradi; Gilda Saluta; Gregory L Kucera; Cynthia S Day; Ulrich Bierbach
Journal:  Bioorg Med Chem Lett       Date:  2009-05-18       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.